← Back
Orchestra BioMed Holdings
OBIO · listed on Nasdaq · worth $355.22 million
$5.91
−2.96% on Oct 30
Six insider buys in the last year, $169.9K in all. None in the last two weeks.
Green dot = an insider bought red = sold◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
33.0M shares
55% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, four insiders bought Orchestra BioMed Holdings stock and one insider sold. Every one of the 4 sales is marked on its filing as planned in advance; all by company executives.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
Director
Eric S. Fain
Bought $82.6K on May 14 — 20,000 shares at $4.13, held through a trust or family, 22% of what they now own.
1 of 1 earlier purchase did better than the S&P 500
Director
Jason Aryeh
Bought $35K on May 15 — 8,971 shares at $3.90, 7.6% of what they now own.
1 of 1 earlier purchase did better than the S&P 500
See Remarks
David P. Hochman
Bought $20.4K on Nov 14, 2025 — 5,000 shares at $4.07, 0.8% of what they now own.
1 of 1 earlier purchase did better than the S&P 500
Planned sales
Form 144 notices filed for Orchestra BioMed Holdings in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
Darren Sherman filed to sell 15,000 shares on 1 Oct; sold 15,000 by 1 Oct10b5-1 plan adopted 18 Dec 2025 · Notice on SEC.gov
Darren Sherman filed to sell 15,000 shares on 1 Sep; sold 15,000 by 1 Sep10b5-1 plan adopted 18 Dec 2025 · Notice on SEC.gov
Darren Sherman filed to sell 15,000 shares on 3 Aug; sold 15,000 by 3 Aug10b5-1 plan adopted 18 Dec 2025 · Notice on SEC.gov
All reports
Every insider trade and SEC report we hold for Orchestra BioMed Holdings.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Oct 2SoldDarren ShermanOct 2 · Traded Oct 1 · See Remarks · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.15,000 @ $6.36$95.4K
Sep 2SoldDarren ShermanSep 2 · Traded Sep 1 · See Remarks · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.15,000 @ $4.94$74.1K
Aug 28BoughtDarren ShermanAug 28 · Traded Aug 26 · See Remarks+100%via a trust or family2,000 @ $5.33$10.7K
Aug 4SoldDarren ShermanAug 4 · Traded Aug 3 · See Remarks · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.15,000 @ $4.09$61.4K
Jul 2SoldDarren ShermanJul 2 · Traded Jul 1 · See Remarks · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.15,000 @ $4.27$64K
13 more with Pro →Analysts, earnings and news
Analysts' price target
$12.33 average
6 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
3 of 3 quarters above
Q2 '26−$0.37 a share+$0.00
Q4 '25$0.26 a share+$0.64
Q3 '25−$0.40 a share+$0.03